Please assess the completion status of the following clinical trial:

Trial Title: Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria~* Levodopa-responsive with severe motor fluctuations~* Recognizable off and on state (motor fluctuations) confirmed by diary~Exclusion Criteria:~* Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism~* Undergone surgery for the treatment of PD~* Contraindications to levodopa (such as narrow angle glaucoma)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levodopa-Carbidopa Intestinal Gel (LCIG) (Type: EXPERIMENTAL): All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances.

Based on this trial design, predict the completion outcome and termination type (if applicable).